Abou-Alfa Ghassan K
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
Semin Oncol. 2006 Dec;33(6 Suppl 11):S79-83. doi: 10.1053/j.seminoncol.2006.10.015.
Advanced and metastatic hepatocellular carcinomas (HCC) are challenging to treat, and no cytotoxic agents have impacted survival. The underlying liver cirrhosis that commonly accompanies HCC provides an additional challenge; indeed, functional scoring of cirrhosis and HCC is a critical component of patient evaluation. Currently, the molecular biology and pathogenesis of HCC are being increasingly investigated, which may lead to better understanding of the evolution of the disease, especially differing etiologies and identification of survival genes that may affect outcome. Early studies of targeted therapies in HCC have shown disease stabilization, and an increased understanding of the mechanism(s) of these novel agents combined with correlative studies may lead to the identification of an active agent or combination of agents that impacts the natural history of HCC.
晚期和转移性肝细胞癌（HCC）的治疗具有挑战性，尚无细胞毒性药物能影响患者生存率。HCC常伴有的潜在肝硬化带来了额外挑战；事实上，对肝硬化和HCC进行功能评分是患者评估的关键组成部分。目前，对HCC的分子生物学和发病机制的研究日益深入，这可能有助于更好地理解该疾病的演变，尤其是不同的病因以及可能影响预后的生存基因的鉴定。HCC靶向治疗的早期研究已显示疾病稳定，对这些新型药物作用机制的深入了解以及相关研究可能会促使发现一种或多种能影响HCC自然病程的活性药物或联合用药方案。
